ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
ASLAN Pharmaceuticals (Nasdaq: ASLN), a biopharmaceutical company focused on immunology, announces participation in the Jefferies London Healthcare Conference from November 15 to 17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq: ASLN), a biopharmaceutical company focused on immunology, announces participation in the Jefferies London Healthcare Conference from November 15 to 17, 2022. CEO Dr. Carl Firth and CBO Mr. Stephen Doyle will meet with investors at the Waldorf Hilton hotel in London. ASLAN is developing innovative treatments including eblasakimab for atopic dermatitis and farudodstat for autoimmune diseases. For more details, visit www.aslanpharma.com.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was +3.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.
Please contact your Jefferies representative to request a one-on-one meeting with management.
About ASLAN Pharmaceutical
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat, a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.